Marguerite Davis

Marguerite Davis is a clinical data analyst at Foresite Capital and contributes to due diligence and research and development evaluation of investment opportunities. She joined the investment team in 2022.

Marguerite brings scientific expertise, and project and alliance management experience from both academia and industry to Foresite Capital. In her prior role as R&D Operations Director at Cabaletta Bio, she managed several cross-functional teams spanning labs at PENN and Cabaletta, commercial manufacturing facilities, and clinical sites and supported regulatory submissions for autologous cell therapies for auto-immune disease. Previously, she spent five years as senior project manager for a wide range of rare disease-focused programs at the Gene Therapy Program at the University of Pennsylvania. She implemented nonclinical partnerships, regulatory submissions, and early BD for multiple emergent start-up gene therapy companies including RegenxBio and Passage Bio.